Login to Your Account


18-month-old Mabspace aims to fast track FOBs in China for cancer, CKD

By Shannon Ellis
Staff Writer

Wednesday, August 6, 2014

SHANGHAI – For Xueming Qian, CEO and founder of Mabspace Co. Ltd., an antibody discovery engine based in Suzhou, the writing was on the wall. While pharma was de-emphasizing early stage research and putting it into the hands of biotechs in the U.S., the economy in China had hit an inflection point, the momentum was building. China was the place to be.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription